OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
RVTY$96.3860

Revvity Inc

Advanced Medical Equipment & TechnologyVerified

Revvity Inc has a market price of $96.38, with a market capitalization of $10.78 billion, indicating a high valuation relative to its net income of $26.01 million. The company's price-to-earnings ratio is 414.24, which is significantly higher than typical industry averages, suggesting that the market is pricing in high future growth expectations. The price-to-book ratio of 1.37 indicates that the company's market value is slightly above its book value, reflecting investor confidence in its intangible assets and future earnings potential. In terms of profitability, Revvity Inc has a return on equity of 0.33% and a return on assets of 0.19%, which are both below the industry median for the Advanced Medical Equipment & Technology sector. This suggests that the company is not generating strong returns relative to its equity and asset base. The operating margin, calculated as operating income of $44.12 million divided by revenue of $649.92 million, is 6.79%, which is also below the industry median, indicating that the company is not as efficient in converting revenue into operating profit as its peers. Revvity Inc's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This lack of diversification could expose the company to higher risks if demand in its primary market or product line declines. The company's revenue concentration in a single segment may also limit its ability to adapt to changing market conditions or to capitalize on new opportunities in other areas. The company's growth trajectory is expected to be moderate, with no significant revenue growth projected in the current fiscal year. The company's free cash flow of $110.01 million and operating cash flow of $147.56 million indicate that it has sufficient liquidity to fund operations and potentially invest in growth initiatives. However, the company's capital expenditure of -$17.84 million suggests that it is not currently investing heavily in new projects or infrastructure, which could limit its long-term growth potential. Revvity Inc faces a medium liquidity risk, as indicated by its current ratio of 2.23, which is above 1 but not significantly so. The company's debt-to-equity ratio of 0.49 suggests that it is not overly leveraged, but it does have a long-term debt of $3.88 billion, which could become a concern if interest rates rise or if the company's credit rating is downgraded. The risk assessment also notes that net cash is negative after subtracting total debt, which could indicate that the company is using its cash reserves to service its debt obligations. Recent events, as disclosed in the company's financial filings, include a focus on maintaining strong cash flow and managing debt levels. The company has not announced any major new projects or acquisitions in the recent past, and its capital expenditure has been negative, suggesting a conservative approach to capital spending. The company's management has also emphasized the importance of maintaining a strong balance sheet and liquidity position to support its operations and growth initiatives.

30-day price · RVTY+5.65 (+6.4%)
Low$81.22High$103.00Close$93.97As of17 May, 00:00 UTC
Profile
CompanyRevvity Inc
TickerRVTY.K
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. Revvity Inc is a provider of advanced medical equipment and technology, primarily focused on life sciences tools and services.

Classification. Revvity Inc is classified under the Healthcare economic sector, Healthcare Services & Equipment business sector, and Advanced Medical Equipment & Technology industry with a confidence level of 0.92.

Revvity Inc has a market price of $96.38, with a market capitalization of $10.78 billion, indicating a high valuation relative to its net income of $26.01 million. The company's price-to-earnings ratio is 414.24, which is significantly higher than typical industry averages, suggesting that the market is pricing in high future growth expectations. The price-to-book ratio of 1.37 indicates that the company's market value is slightly above its book value, reflecting investor confidence in its intangible assets and future earnings potential. In terms of profitability, Revvity Inc has a return on equity of 0.33% and a return on assets of 0.19%, which are both below the industry median for the Advanced Medical Equipment & Technology sector. This suggests that the company is not generating strong returns relative to its equity and asset base. The operating margin, calculated as operating income of $44.12 million divided by revenue of $649.92 million, is 6.79%, which is also below the industry median, indicating that the company is not as efficient in converting revenue into operating profit as its peers. Revvity Inc's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This lack of diversification could expose the company to higher risks if demand in its primary market or product line declines. The company's revenue concentration in a single segment may also limit its ability to adapt to changing market conditions or to capitalize on new opportunities in other areas. The company's growth trajectory is expected to be moderate, with no significant revenue growth projected in the current fiscal year. The company's free cash flow of $110.01 million and operating cash flow of $147.56 million indicate that it has sufficient liquidity to fund operations and potentially invest in growth initiatives. However, the company's capital expenditure of -$17.84 million suggests that it is not currently investing heavily in new projects or infrastructure, which could limit its long-term growth potential. Revvity Inc faces a medium liquidity risk, as indicated by its current ratio of 2.23, which is above 1 but not significantly so. The company's debt-to-equity ratio of 0.49 suggests that it is not overly leveraged, but it does have a long-term debt of $3.88 billion, which could become a concern if interest rates rise or if the company's credit rating is downgraded. The risk assessment also notes that net cash is negative after subtracting total debt, which could indicate that the company is using its cash reserves to service its debt obligations. Recent events, as disclosed in the company's financial filings, include a focus on maintaining strong cash flow and managing debt levels. The company has not announced any major new projects or acquisitions in the recent past, and its capital expenditure has been negative, suggesting a conservative approach to capital spending. The company's management has also emphasized the importance of maintaining a strong balance sheet and liquidity position to support its operations and growth initiatives.
Key takeaways
  • Revvity Inc has a high price-to-earnings ratio of 414.24, indicating that the market is pricing in high future growth expectations.
  • The company's return on equity of 0.33% and return on assets of 0.19% are below the industry median, suggesting that it is not generating strong returns relative to its equity and asset base.
  • Revvity Inc's revenue is concentrated in a single business segment, which could expose the company to higher risks if demand in its primary market or product line declines.
  • The company has a moderate liquidity risk, as indicated by its current ratio of 2.23, and a debt-to-equity ratio of 0.49, suggesting that it is not overly leveraged but has a significant long-term debt obligation.
  • # RATIONALES
  • margin_outlook_rationale: The company's operating margin is expected to remain stable due to consistent revenue and controlled operating expenses.
  • rd_outlook_rationale: Research and development spending is expected to remain moderate as the company focuses on optimizing existing product lines.
  • capex_outlook_rationale: Capital expenditure is expected to remain low as the company prioritizes cash flow management over new infrastructure investments.
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$649.9M
Gross profit$355.0M
Operating income$44.1M
Net income$26.0M
R&D
SG&A
D&A
SBC
Operating cash flow$147.6M
CapEx-$17.8M
Free cash flow$110.0M
Total assets$13.43B
Total liabilities$5.59B
Total equity$7.85B
Cash & equivalents$998.1M
Long-term debt$3.88B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$3.83B$1.26B$943.2M$1.12B
FY-3$3.31B$742.7M$569.2M$818.7M
FY-2$2.75B$300.6M$693.1M$495.0M
FY-1$2.76B$346.7M$270.4M$589.9M
FY0$2.86B$356.6M$241.2M$538.9M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$15.00B$7.14B$618.3M
FY-3$14.13B$7.38B$454.4M
FY-2$13.56B$7.87B$913.2M
FY-1$12.39B$7.67B$1.16B
FY0$12.17B$7.25B$919.9M
PeriodOCFCapExFCFSBC
FY-4$1.41B-$99.9M$1.12B
FY-3$679.8M-$85.6M$818.7M
FY-2$91.3M-$81.4M$495.0M
FY-1$628.3M-$86.6M$589.9M
FY0$582.9M-$73.5M$538.9M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$649.9M$44.1M$26.0M$110.0M
FQ-6$691.7M$85.7M$55.4M$149.3M
FQ-5$684.0M$98.2M$94.4M$170.1M
FQ-4$729.4M$118.8M$94.6M$160.4M
FQ-3$664.8M$72.2M$42.2M$114.7M
FQ-2$720.3M$90.8M$53.9M$130.8M
FQ-1$698.9M$81.9M$46.7M$122.7M
FQ0$772.1M$111.7M$98.4M$170.7M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$13.43B$7.85B$998.1M
FQ-6$13.42B$7.87B$1.25B
FQ-5$12.77B$7.92B$1.23B
FQ-4$12.39B$7.67B$1.16B
FQ-3$12.36B$7.64B$1.14B
FQ-2$12.36B$7.56B$991.8M
FQ-1$12.14B$7.38B$931.4M
FQ0$12.17B$7.25B$919.9M
PeriodOCFCapExFCFSBC
FQ-7$147.6M-$17.8M$110.0M
FQ-6$306.2M-$39.9M$149.3M
FQ-5$454.1M-$62.2M$170.1M
FQ-4$628.3M-$86.6M$160.4M
FQ-3$128.2M-$16.0M$114.7M
FQ-2$262.5M-$34.9M$130.8M
FQ-1$401.0M-$53.4M$122.7M
FQ0$582.9M-$73.5M$170.7M
Valuation
Market price$96.38
Market cap$10.78B
Enterprise value$13.65B
P/E414.2
Reported non-GAAP P/E
EV/Revenue21.0
EV/Op income309.5
EV/OCF92.5
P/B1.4
P/Tangible book1.4
Tangible book$7.85B
Net cash-$2.88B
Current ratio2.2
Debt/Equity0.5
ROA0.2%
ROE0.3%
Cash conversion5.7%
CapEx/Revenue-2.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Advanced Medical Equipment & Technology · cohort 109 companies
MetricRVTYActivity
Op margin6.8%-19.9% medp25 -150.5% · p75 8.7%above median
Net margin4.0%-18.4% medp25 -146.8% · p75 8.0%above median
Gross margin54.6%49.9% medp25 36.2% · p75 66.3%above median
R&D / revenue6.2% medp25 4.7% · p75 12.0%
CapEx / revenue-2.8%-3.5% medp25 -7.8% · p75 -1.4%above median
Debt / equity49.0%14.5% medp25 0.9% · p75 54.2%above median
Observations
IR observations
Mean price target112.08 USD
Median price target110.00 USD
High price target140.00 USD
Low price target90.00 USD
Mean recommendation2.37 (1=strong buy, 5=strong sell)
Strong-buy count3.00
Buy count6.00
Hold count10.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate5.39 USD
Last actual EPS5.06 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-16 12:26 UTC#4617a5c0
Market quoteclose USD 91.15 · shares 0.11B diluted
no public URL
2026-05-16 12:26 UTC#3c7a65f0
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 06:47 UTCJob: 66db3fc0